Market News AIOpen the app

Acrivon Therapeutics shared its Q3 2026 results and announced new updates on its drug trials.

ResultsRead the original at SEC EDGAR
Good for ACRV

Acrivon reported early patient benefit from a cancer drug and added immune-disease programs. These advances support its outlook, though its $77.8 million cash is expected to fund operations only into the fourth quarter of 2027, and a key trial review is still pending.

ACRV · Acrivon Therapeutics, Inc.

AI read · Good for ACRV

The AI's read

The reported patient results give Acrivon early signs that its cancer drug may help some patients. Its new immune-disease programs add another area to develop. The planned review of another cancer trial has not happened yet, and the company expects its cash to last into the fourth quarter of 2027.

Get alerts for ACRV

Follow Acrivon Therapeutics, Inc. (ACRV) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ACRV
Free on the App Store and Google Play, or on the web.